Ibuprofen product-specific bioequivalence guidance EMA [Regulatives / Guidelines]

posted by qualityassurance – Jordan, 2021-09-26 07:45 (27 d 21:58 ago) – Posting: # 22599
Views: 513

Dear Forum members,

The question is related to product-specific bioequivalence guidance (EMA) for Ibuprofen draft and Final.

The former indicates that the method should be enantioselective and the later indicates the opposite. Of course we should consider the final guidance and not the draft.

However, all conditions are fulfilled for (⇒ chiral analytics) and also found some public assessment report where chiral method was used and Pharmacokinetic data were submitted for both enantiomers.

Please suggest, whether we should go for chiral or achiral assay?

Thank you.

Complete thread:

 Admin contact
21,753 posts in 4,548 threads, 1,544 registered users;
online 23 (0 registered, 23 guests [including 5 identified bots]).
Forum time: Sunday 05:43 CEST (Europe/Vienna)

They were “so intent of making everything numerical”
that they frequently missed seeing
what was there to be seen.    Barbara McClintock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz